In a set­back, Glob­al Blood Ther­a­peu­tics scraps IPF pro­gram as lead drug floun­ders in proof-of-con­cept tri­als

It’s all or noth­ing for Glob­al Blood Ther­a­peu­tics’ clin­i­cal tri­al pro­gram for sick­le cell dis­ease.

The South San Fran­cis­co-based biotech an­nounced this morn­ing that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER